In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

Processa Pharmaceuticals has dosed the first subject in its Phase II clinical trial of Next Generation Capecitabine (NGC-Cap) to treat patients with advanced or metastatic breast cancer.

Background. A 66-year-old woman with metastatic mammary carcinoma, who was being treated with capecitabine, contracted a herpes zoster infection that was treated with the antiviral drug brivudin.

In view of the patient's long progression-free survival (12.9 months), we decided to resume intramuscular octreotide (30 mg every 3 weeks) with capecitabine and liposomal doxorubicin chemotherapy ...

Market research from the manufacturers of capecitabine indicates that the clinical community has voted with its empirical feet—it is relatively rare for US-based oncologists to prescribe the ...